Featured
Featured Videos
Bioprocessing in Boston: GEN Reports Live from BPI 2024
- Seres Therapeutics, developer of the first microbiome therapy platform
- Ring Therapeutics, a developer of gene therapies based on its commensal virome platform
- Cellarity, which aims to design medicines targeting the full cellular and molecular complexity of disease as opposed to a single molecular target
- Abiologics, a developer of programmable medicines combining generative artificial intelligence and high throughput chemical protein synthesis (it emerged from stealth mode in July)
- Cygnal Therapeutics, now part of Sonata Therapeutics, whose Network Medicines™ reprogram diseased cells to become “coordinators of cure” by releasing a defined array of signals designed to precisely coordinate multicellular networks to drive disease resolution
Avak Kahvejian, PhD, Recounts His Journey from Sequencing Pioneer to Flagship General Partner on “Close to the Edge”
Even though biomanufacturing experiences ups and downs in demand, it recognizes what is constant—the need to adapt. For example, as the CEO of a leading CDMO quoted in this issue of GEN observes, biotech and biopharma clients appear to be tightening their budgets and pruning their pipelines. And yet long-term trends look promising, especially given the growing importance of therapeutic modalities. In this issue, both near-term challenges and long-term opportunities are discussed in our A-List of Top 10 CDMOs. But what should biomanufacturers do when demand surges? That’s covered in this issue, too. And, as always, GEN addresses developments of various kinds. Besides offering biomanufacturing coverage, this issue presents articles on gene therapy, digital twins, phage therapy, and biomarker development.